Golden Recursion Inc. logoGolden Recursion Inc. logo
Advanced Search
Sherlock Biosciences

Sherlock Biosciences

Sherlock Biosciences is a Cambridge, Massachusetts-based company founded in 2019 by David R. Walt, Rahul Dhanda, Feng Zhang, Jim Collins, Deborah Hung, Jonathan Gootenberg, Omar Abudayyeh, Pardis Sabeti and Todd Golub.

Sherlock Biosciences is a synthetic biology company offering a medical diagnostics and engineering biology platform that is headquartered in Cambridge, Massachusetts and was founded in 2019 by Feng Zhang, Jim Collins, David R. Walt, Rahul K. Dhanda, Omar Abudayyeh, Todd Golub, Jonathan Gootenberg, Deborah Hung, and Pardis Sabeti.


SHERLOCK (Specific High sensitivity Enzymatic Reporter unLOCKing or INternal Splint-Pairing Expression Cassette Translation Reaction) is a CRISPR based technology for detecting unique genetic sequences of any DNA or RNA sequence from any organism or pathogen. SHERLOCK is made for the detection of single molecules part of nucleic acids targets by amplifying genetic sequences and programming CRISP to detect specific genetic sequences within each amplified sample, releasing a signal when a certain genetic sequence is detected.


INSPECTR (Internal Splint-Pairing Expression Cassette Translation Reaction) is a synthetic biology platform that uses freeze-dried synthetically made gene networks as programmable molecular diagnostic devices. INSPECTR can be programmed to find targets differing by a single nucleotide without the need for scientific instruments and at room temperature. When INSPECTR finds a desired nucleic acid target is produces a reporter protein which can be detected as a diagnostic readout.

Coronavirus diagnostics

Sherlock Biosciences is developing a CRISPR-based diagnostic test for coronavirus after the outbreak of a new coronavirus strain, SARS-CoV-2 (2019-nCoV) that was declared a global emergency by the World Health Organization (WHO). The coronavirus strain has more recently been renamed SARS-CoV-2 with the disease called COVID-19 (coronavirus disease).

Sereis A

On April 23, 2019 Sherlock Biosciences completed their series A funding round with $49 million in funding from Northpond Ventures (lead investor), Baidu Ventures (lead investor), the Open Philanthropy Project, and other investors. the co-founder, president, and CEO of Sherlock Biosciences gave the following statement to reporters regarding the companies series A funding round:

Their support will be vital as we work to harness and direct the power of our SHERLOCK and INSPECTR platforms to develop rapid and more effective diagnostic tests through Engineering Biology and Deep Learning tools that can be performed anywhere, such as testing in the field or home.


March 8, 2022
Sherlock Biosciences raises a $80,000,000 series B round.
May 2020
Sherlock Biosciences raises a $7,500,000 grant from Open Philanthropy Project.
April 23, 2019
Sherlock Biosciences raises a $31,000,000 series A round from Northpond Ventures.

Funding rounds


Further Resources



Andrea Park
July 12, 2021
The game is afoot for Bryan Dechairo, newly named president and CEO of Sherlock Biosciences. He'll take over from Rahul Dhanda, co-founder of the company, who will stay on as a member of Sherlock's board of directors through the end of this year before stepping into a strategic adviser role in 2022.
May 3, 2021
The 221b Foundation, a nonprofit organization established by Sherlock Biosciences to address the global COVID-19 pandemic while promoting diverse representation in STEM, and LogicInk, a lifestyle sensor company developing bio-chemical Signals that can be worn or applied daily, today announced the organizations have entered into a license agreement to enable LogicInk to utilize Sherlock Biosciences' CRISPR technology
BioSpace Editorial Staff
June 8, 2020
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 8, 2020.
June 8, 2020
Sherlock Biosciences and Integrated DNA Technologies (IDT) today announced the companies have entered into a strategic collaboration to enable large-scale manufacturing of the SherlockTM CR
BioSpace Editorial Staff
May 8, 2020
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 8, 2020.


Golden logo
By using this site, you agree to our Terms & Conditions.